Advertisement

Topics

FDA Approves Vertex’s Kalydeco for 600+ Cystic Fibrosis Patients with One of Five Residual Mutations

11:28 EDT 2 Aug 2017 | Speciality Pharma Journal

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) ages 2 and older who have one of five residual function mutations that result in a splicing defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. …

Original Article: FDA Approves Vertex’s Kalydeco for 600+ Cystic Fibrosis Patients with One of Five Residual Mutations

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Vertex’s Kalydeco for 600+ Cystic Fibrosis Patients with One of Five Residual Mutations"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...